|
|
Blood, 15 February 2004, Vol. 103, No. 4, pp. 1202-1210.
Prepublished online as a Blood First Edition Paper on October 23, 2003; DOI 10.1182/blood-2003-07-2281.
 Previous Article | Table of Contents | Next Article 
REVIEW ARTICLES
Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL
Tait D. Shanafelt,
Susan M. Geyer, and
Neil E. Kay
From the Division of Hematology, Mayo Clinic, Rochester, MN.
Heterogeneity in the clinical behavior of patients with chronic lymphocytic leukemia (CLL) makes it difficult for physicians to accurately identify which patients may benefit from an early or more aggressive treatment strategy and to provide patients with relevant prognostic information. Given the potential efficacy of newer therapies and the desire to treat patients at "optimum" times, it is more important than ever to develop sensitive stratification parameters to identify patients with poor prognosis. The evolution of risk stratification models has advanced from clinical staging and use of basic laboratory parameters to include relevant biologic and genetic features. This article will review the dramatic progress in prognostication for CLL and will propose statistical modeling techniques to evaluate the utility of these new measures in predictive models to help determine the optimal combination of markers to improve prognostication for individual patients. This discussion will also elaborate which markers and tools should be used in current clinical practice and evaluated in ongoing clinical trials.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Gachard, A. Salviat, C. Boutet, C. Arnoulet, F. Durrieu, B. Lenormand, S. Lepretre, S. Olschwang, F. Jardin, M. Lafage-Pochitaloff, et al.
Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method
Haematologica,
February 1, 2008;
93(2):
215 - 223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Gattei, P. Bulian, M. I. Del Principe, A. Zucchetto, L. Maurillo, F. Buccisano, R. Bomben, M. Dal-Bo, F. Luciano, F. M. Rossi, et al.
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia
Blood,
January 15, 2008;
111(2):
865 - 873.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Stamatopoulos, N. Meuleman, B. Haibe-Kains, H. Duvillier, M. Massy, P. Martiat, D. Bron, and L. Lagneaux
Quantification of ZAP70 mRNA in B Cells by Real-Time PCR Is a Powerful Prognostic Factor in Chronic Lymphocytic Leukemia
Clin. Chem.,
October 1, 2007;
53(10):
1757 - 1766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Durig, P. Ebeling, F. Grabellus, U. R. Sorg, M. Mollmann, P. Schutt, J. Gothert, L. Sellmann, S. Seeber, M. Flasshove, et al.
A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease
Cancer Res.,
September 15, 2007;
67(18):
8653 - 8661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Wolff, A. Bagg, L. D. Cooley, G. W. Dewald, B. A. Hirsch, P. B. Jacky, K. W. Rao, P. N. Rao, and the Association for Molecular Pathology Clinical P
Guidance for Fluorescence in Situ Hybridization Testing in Hematologic Disorders
J. Mol. Diagn.,
April 1, 2007;
9(2):
134 - 143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bomben, M. Dal Bo, D. Capello, D. Benedetti, D. Marconi, A. Zucchetto, F. Forconi, R. Maffei, E. M. Ghia, L. Laurenti, et al.
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study
Blood,
April 1, 2007;
109(7):
2989 - 2998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Le, M. K. Hailer, S. Buhrow, Q. Wang, K. Flatten, P. Pediaditakis, K. C. Bible, L. D. Lewis, E. A. Sausville, Y.-P. Pang, et al.
Inhibition of Mitochondrial Respiration as a Source of Adaphostin-induced Reactive Oxygen Species and Cytotoxicity
J. Biol. Chem.,
March 23, 2007;
282(12):
8860 - 8872.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ocana, L. Delgado-Perez, A. Campos-Caro, J. Munoz, A. Paz, R. Franco, and J. A. Brieva
The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells
Haematologica,
March 1, 2007;
92(3):
349 - 356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Shi, D. White, L. He, R. L. Miller, and D. E. Spaner
Toll-like Receptor-7 Tolerizes Malignant B Cells and Enhances Killing by Cytotoxic Agents
Cancer Res.,
February 15, 2007;
67(4):
1823 - 1831.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Kay, S. M. Geyer, T. G. Call, T. D. Shanafelt, C. S. Zent, D. F. Jelinek, R. Tschumper, N. D. Bone, G. W. Dewald, T. S. Lin, et al.
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Blood,
January 15, 2007;
109(2):
405 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt and N. E. Kay
Comprehensive Management of the CLL Patient: A Holistic Approach
Hematology,
January 1, 2007;
2007(1):
324 - 331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Venugopal and S. A. Gregory
Lymphoproliferative disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
265 - 297.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, T. E. Witzig, S. R. Fink, R. B. Jenkins, S. F. Paternoster, S. A. Smoley, K. J. Stockero, D. M. Nast, H. C. Flynn, R. C. Tschumper, et al.
Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
October 1, 2006;
24(28):
4634 - 4641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, J. C. Byrd, T. G. Call, C. S. Zent, and N. E. Kay
Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia.
Ann Intern Med,
September 19, 2006;
145(6):
435 - 447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Deaglio, T. Vaisitti, S. Aydin, E. Ferrero, and F. Malavasi
In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia
Blood,
August 15, 2006;
108(4):
1135 - 1144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Lin, M. A. Glenn, R. J. Harris, A. D. Duckworth, S. Dennett, J. C. Cawley, M. Zuzel, and J. R. Slupsky
c-Abl Expression in Chronic Lymphocytic Leukemia Cells: Clinical and Therapeutic Implications.
Cancer Res.,
August 1, 2006;
66(15):
7801 - 7809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Koller, B. N. Bekele, X. Zhou, C. Park, Z. Estrov, S. O'Brien, M. Keating, I. Jilani, F. J. Giles, H. M. Kantarjian, et al.
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia
Blood,
August 1, 2006;
108(3):
1001 - 1006.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, D. Jelinek, R. Tschumper, S. Schwager, G. Nowakowski, G. W. DeWald, and N. E. Kay
Cytogenetic Abnormalities Can Change During the Course of the Disease Process in Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
July 1, 2006;
24(19):
3218 - 3219.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Novak, D. M. Grote, S. C. Ziesmer, M. P. Kline, M. K. Manske, S. Slager, T. E. Witzig, T. Shanafelt, T. G. Call, N. E. Kay, et al.
Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders
J. Clin. Oncol.,
February 20, 2006;
24(6):
983 - 987.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Kay
Treatment and evaluation of CLL: a complicated affair
Blood,
February 1, 2006;
107(3):
848 - 848.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. McWhirter, A. Kretz-Rommel, A. Saven, T. Maruyama, K. N. Potter, C. I. Mockridge, E. P. Ravey, F. Qin, and K. S. Bowdish
Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation
PNAS,
January 24, 2006;
103(4):
1041 - 1046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Khouri
Reduced-Intensity Regimens in Allogeneic Stem-Cell Transplantation for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Hematology,
January 1, 2006;
2006(1):
390 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nabhan and J. D. Bitran
Chronic Lymphocytic Leukemia: To Transplant or Not to Transplant... That Is the Question?
J. Clin. Oncol.,
November 1, 2005;
23(31):
8126 - 8127.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Caballero, J. A. Garcia-Marco, R. Martino, V. Mateos, J. M. Ribera, J. Sarra, A. Leon, G. Sanz, J. de la Serna, R. Cabrera, et al.
Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)
Clin. Cancer Res.,
November 1, 2005;
11(21):
7757 - 7763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Moreno, N. Villamor, D. Colomer, J. Esteve, R. Martino, J. Nomdedeu, F. Bosch, A. Lopez-Guillermo, E. Campo, J. Sierra, et al.
Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 20, 2005;
23(15):
3433 - 3438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Deaglio, T. Vaisitti, L. Bergui, L. Bonello, A. L. Horenstein, L. Tamagnone, L. Boumsell, and F. Malavasi
CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival
Blood,
April 15, 2005;
105(8):
3042 - 3050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, Y. K. Lee, N. D. Bone, A. K. Strege, V. L. Narayanan, E. A. Sausville, S. M. Geyer, S. H. Kaufmann, and N. E. Kay
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine
Blood,
March 1, 2005;
105(5):
2099 - 2106.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
